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Approximately one-third of all breast cancer patients experience local recurrence of their tumor after initial treatment. As initial
treatment often employs the use of radiation therapy (RT), the standard of care for local breast cancer recurrence after initial
breast conserving therapy has traditionally been surgical intervention with mastectomy. However, recent attempts to preserve the
intact breast after recurrence with local excision have revealed a potential need for RT in addition to repeat breast conserving
surgery as rates of local failure with resection alone remain high. Additionally, local recurrence following initial mastectomy and
chest wall RT can be treated with reirradiation to increase local control. Repeating RT, however, in a previously irradiated area,
is a complex treatment strategy, as the clinician must carefully balance maximizing treatment eﬀectiveness while minimizing
treatment-related toxicity. As a result, physicians have been hesitant to treat recurrent disease with repeat RT with limited data.
Results from the current literature are promising and current clinical trials are underway to explore reirradiation modalities which
will provide additional information on treatment-related toxicity and outcomes. This paper will review the current literature on
repeat radiation therapy for locally recurrent breast cancer.
1. Introduction
Of the nearly 300,000 cases of invasive and in situ breast
cancers diagnosed in 2010 alone, 20–40% of these patients
will experience a local recurrence (LR) and approximately
half of those will have isolated recurrences [1]. Optimal local
control is noted to be important for patient outcomes. Local
recurrences still occur at rates reported in large, randomized
trials between 3–20% rate for patients receiving breast con-
serving therapy (BCT) and a 2–12% for patients who have
undergone mastectomy [2–4]. Accordingly, treatment of
locally recurrent breast cancer remains important in the care
of breast cancer patients. Patient and tumor characteristics,
as well as initial treatment, have a significant impact on
the treatment options oﬀered for recurrent disease. Given
the heterogeneous nature of local breast cancer recurrence,
several treatment options are available and in this paper we
will further outline the role of radiation therapy (RT) which
is one such treatment modality.
2. Recurrence in Patients Treated Initially
with BCT
Mastectomy remains the standard of care for patients with
in-breast tumor recurrence (IBTR) after initial treatment
with BCT. Mastectomy in the setting of recurrent disease
results in a second local recurrence rate of 2–31% [5]. In
patients with an in-breast tumor recurrence (IBTR), five-
year overall survival rates after mastectomy range from 52
to 84% in various series [6–10]. While mastectomy remains
the current standard of care for IBTR, a growing body
of literature describes repeat BCT in the setting of locally
recurrent disease.
2.1. Repeat Breast Conserving Therapy without Reirradiation.
More women are choosing to preserve their breast in the
setting of recurrence with repeat BCT. Initial experiences
with BCT for recurrence focused on partial mastectomy
alone without repeat irradiation. Kurtz et al. reported on 52
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Table 1: Outcomes of patients treated with breast conserving surgery alone following in-breast local recurrence.
Study Number of patients Median followup (months) Local recurrence (%) 5-year overall survival (%)
Kurtz et al. [11] 55 51 32 NR
Abner et al. [12] 16 39 31 81
Salvadori et al. [6] 57 73 19 85
Voogd et al. [13] 16 52 38 NR
Ishitobi et al. [14] 78 40 21.2 NR
NR: not reported.
patients who had received wide local excision for isolated
LR. Patients with mobile tumors less than 2 cm in diameter
and no signs of rapid progression were carefully selected for
breast preservation. In this group, the five-year local control
and cause-specific survival were 79% which are comparable
to results noted with mastectomy. Interestingly, it was noted
that local control was doubled when negative margins were
achieved with local excision on second surgery. Therefore, it
seems that the potential exists to avoid a mastectomy in the
setting of recurrent disease if adequate margins are obtained
[11].
This was explored further by Salvadori et al. in a large
series reporting on patients receiving a mastectomy or a
local resection for isolated LR. With a median followup of
6 years, the risk of a second local recurrence was significantly
increased in the local resection group at 19% versus 4% for
total mastectomy [6]. These results were echoed by Abner et
al. and Voogd et al., showing a LR rate of 31% at 3.5 years
and 38% at 4.5 years, respectively, with a local resection alone
(Table 1) [12–14].
While these rates of recurrence are significantly greater
than those from total mastectomy, they are comparable
to the 35% risk of recurrence found in upfront breast
conserving surgery without the addition of RT. This has
led investigation into the feasibility of repeat irradiation to
the IBTR recurrence after resection to minimize the risk of
local recurrence. To date, repeat radiation has been described
using various treatment techniques such as external beam
radiation therapy (EBRT), intraoperative radiation therapy
(IORT), and brachytherapy.
3. Second Breast Conserving Therapy with
Repeat Radiation Therapy
Overall, the published data on reirradiation have shown
promising results. In terms of local control, reported rates
range from 77–100%, with the limited available prospective
data revealing a very favorable 7–11% rate of second LR.
Furthermore, acceptable rates of toxicity and cosmesis have
been obtained in all reported series, regardless of variations
in RT technique for repeat partial breast irradiation. The
methodologies previously utilized in the literature will be
reviewed, along with the associated outcomes data.
3.1. External Beam Radiation Therapy. As early as the mid-
1980s, EBRT was employed to reirradiate patients with breast
cancer recurrence. Deutsch has reported on approximately
40 women with IBTR following partial mastectomy and
radiation therapy. Initial RT consisted of 50Gy to the whole
breast in 2Gy fractions with or without tumor bed boost.
At the time of recurrence, a median of 63 months from
initial treatment, partial breast reirradiation (PBrI) to a
dose of 50Gy in 2Gy daily fractions was delivered to the
entire operative quadrant using electrons of appropriate
energy. Deutsch showed that among 39 patients at a median
followup of 52 months, 77% of patients had an intact breast
free of tumor. Treatment was well tolerated but alteration in
skin pigmentation was reported as well as 25% of evaluated
patients having fair to poor cosmesis [15].
A heterogeneous group of 29 patients receiving reirradi-
ation with 3D-conformal RT were reviewed by Wu¨rschmidt
et al., of which 4 received second breast conserving therapy.
Cosmetic results were good to excellent with no Grade 3 or
higher toxicity in this small group of patients [16].
The Radiation Therapy Oncology Group (RTOG) is
evaluating a similar treatment approach with external beam
partial breast radiation therapy in its current phase II trial.
The radiation volume will consist of the surgical margin
plus CTV and PTV expansions to generate a 2.5 cm margin
excluding the skin surface. This will result in a significantly
smaller treatment volume (Figure 1) than the initial RT
volume, which usually encompasses the entire breast. Twice
daily fractions of 1.5 Gy will be administered to a total dose
of 45Gy.
3.2. Intraoperative Radiation Therapy. Single institution data
on IORT utilized the Intrabeam device, with a median
applicator size of 4.0 cm (Carl Zeiss, Oberkochen, Germany),
which delivered a median dose of 20Gy to the applicator
surface. In this study, postprocedure margins were noted
to range from 1 to 10mm and after more than 2 years of
followup no local recurrences were noted. IORTwas also well
tolerated with no Grade 3 or higher toxicity and a majority
of excellent or good cosmetic outcomes [17].
3.3. Interstitial Brachytherapy. The use of interstitial bra-
chytherapy as a method of delivering focal radiation in
the setting of locally recurrent breast cancer has been well
documented. A French retrospective study of almost 70
patients who underwent repeat lumpectomy followed by
interstitial brachytherapy revealed promising 5-year OS and
freedom from second local recurrence (FFLR2). Despite the
dissimilar treatment modality, Hannoun-Levi et al. showed
results similar to those of Deutsch. A 77% rate of freedom
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Figure 1: Partial breast radiation therapy plan utilizing external beam radiation therapy with photons. Blue: planning target volume-
evaluation (PTVeval), red: 95% isodose line, yellow: 90% isodose line.
from second local recurrence was noted in 70 patients.
Interestingly, in this group of patients treated with interstitial
brachytherapy, multivariate analysis revealed the subset of
patients treated with 5 or more wires had a markedly
improved FFLR2 of nearly 95% at 5 years. This treatment
course delivered a median of 7.5 years from initial diagnosis
and was also well tolerated with minimal acute toxicity.
A 10% rate of late Grade 3 toxicity was noted, most
commonly fibrosis [18]. While only in abstract form, a much
larger retrospective series of 217 patients receiving second
conservative treatment with lumpectomy and interstitial
brachytherapy was reported on at the World Congress of
Brachytherapy in 2012. The 5-year local recurrence rate was
a promising 5.6% with actuarial OS at 5 years reported as
88.7%. Furthermore, cosmesis was good to excellent in 85%
of patients with an 11% rate of Grade 3 and 4 toxicity noted
[19].
While the aforementioned retrospective data provides
insight on the safety and eﬃcacy of PBrI, limited prospective
data exist for reirradiation in the setting of locally recur-
rent breast cancer. Three prospective trials have reported
encouraging local control rates, with all studies employing
brachytherapy techniques to deliver a second course of
radiation therapy. A phase II trial from Austria enrolled
39 patients with IBTR who refused mastectomy and opted
for a second breast conserving treatment. Similarly, Guix
et al. conducted a study of a second breast conserving
treatment in 36 women with limited-size, low-risk local
recurrence occurring at a greater than 12month interval who
had refused mastectomy. Patients were excluded from both
studies if LR was within 12months of initial treatment. There
was a median interval between treatments of nearly 11 years
in the study by Kauer-Dorner et al., but only 3.2 years in the
Guix et al. study.
Radiation therapy techniques also diﬀered in these two
trials. The Austrian group utilized multicatheter interstitial
pulsed dose rate (PDR) brachytherapy following an R0 repeat
resection. Mean physical, total dose of 50.1 Gy in fractions
of 0.6 to 1Gy was prescribed. Of note, 10 patients had
received chemotherapy and 24 received hormonal therapy.
The Spanish group employed an HDR technique to deliver
30Gy in 12 fractions over a period of 5 days. Adjuvant
chemotherapy was given to 13 patients, while 8 patients
received hormonal therapy [20, 21].
Additionally, a smaller phase I/II study utilized low dose
rate brachytherapy, initially to a total dose of 30Gy in 6
patients. The dose was escalated to 45Gy for the subsequent
9 patients as toxicity was minimal. Consistent with the
majority of data, an admixture of systemic therapy was
reported with a portion of patients receiving chemotherapy
or hormonal therapy [22].
In this phase I/II trial, Chadha et al. reported an 89%
local control rate, but patient numbers were low and median
followup was only 36 months. However, similar 5-year
actuarial local control of 93% was seen in the larger Austrian
study with a median followup of 57 months. In this study, 5-
year OS and DFS were 87% and 77%, respectively. Ten-year
actuarial data were reported in the Spanish study, showing an
OS of 96.7%, DFS of 64.4%, and local control of 89.4%.
Guix et al. reported low treatment-related toxicity, with
no Grade 3 or 4 events reported. Only 4% of patients in this
study had unsatisfactory cosmetic outcomes. Kauer-Dorner
et al. did note Grade 3 breast tissue fibrosis in 1 woman
and 3 women had Grade 3 pain. Poor or unacceptable
cosmesis was documented in 6 patients by independent
observers; however, only 2 patients self-reported this level
of cosmetic outcome. Thus equivalent local tumor control
to mastectomy was obtained by second BCT with good
cosmesis and moderate morbidity. Overall, the addition
of PBrI to repeat breast conserving surgery appears to be
both eﬃcacious and well tolerated (Table 2). However, when
considering the use of a second breast conserving therapy
it is important to remember that the study populations
were highly selected patients with small local recurrences
occurring more than one year from initial treatment [20–
22].
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3.4. Future Directions. Further study of repeat BCT employ-
ing surgery and reirradiation with partial breast is currently
underway in a phase II trial, RTOG 1014. This study will
evaluate the adverse events associated with the use of PBrI
in patients with recurrent breast cancer following a margin-
negative repeat lumpectomy. As in the Austrian study, recur-
rence within 12 months is an exclusion criterion. External
beam radiation therapy is being administered to a total dose
of 45Gy using a 1.5Gy twice daily fractionation. The study
will secondarily evaluate endpoints of local control, freedom
from mastectomy, cosmesis and OS.
4. Recurrence in Patients Who Received
Initial Mastectomy
Guidelines for the treatment of local recurrence in patients
treated initially with mastectomy are slightly more complex
than for those patients who received upfront BCT. The
standard of care is currently surgical resection, if technically
feasible. Similar to patients who had prior BCT, systemic
therapy is to be considered. In patients who have not
previously received RT, the NCCN Guidelines recommend
chest wall and nodal irradiation. There is a large body
of literature demonstrating the use of radiation therapy
for chest wall recurrence, including data on chest wall
reirradiation. However, caution is warranted in repeat chest
wall RT as aggregate doses of 100Gy or higher can pose
significant risk of toxicity such as skin ulceration, brachial
plexopathy, osteonecrosis, rib fracture, and cardiomyopathy.
4.1. Chest Wall Radiation Therapy without Prior RT. In the
context of patients who had not had prior radiation, the
addition of chest wall radiation therapy at the time of
recurrence has well-documented utility for improvement
of local control [23, 24]. Halverson et al. reported the
Washington University experience with chest wall radiation
therapy for local-regional recurrence following mastectomy
[25]. Patients treated to a large RT field encompassing the
entire chest wall, FFR, were 75% and 63% at 5 and 10 years,
compared with 36% and 18% in patients treated to a smaller
field. In this study, field size proved to be an important factor
for freedom from recurrence (FFR) and it was recommended
that the entire chest wall is treated. A radiation dose of 60Gy
seemed to adequately control tumors less than 3 cm in this
study, while only half of larger tumors were controlled by
doses of up to 70Gy.
Another single institution retrospective review [26]
published by Hsi et al. treated patients at the Hospital of
the University of Pennsylvania with a chest wall recurrence
following mastectomy using radiation to a median chest wall
dose of 50Gy along with 10Gy scar boost. At a median
followup of 8.4 years, the ten-year actuarial local control
was 86%, overall survival 72%, and cause specific survival
77% [27]. It was found that patients who had greater than
2-year disease-free interval after mastectomy, isolated chest
wall recurrence, a tumor less than 3 cm, or a completely
resected tumor, seemed to respond most favorable to
radiation.
4.2. Repeat Chest Wall Radiation Therapy. While the addition
of chest wall RT for patients with local recurrence in patients
without previous RT is fairly straightforward, repeat irradia-
tion is more controversial due to the high cumulative doses
that would be achieved and potential toxicity. Local control
with repeat surgery alone remains unacceptable with 5-year
local control rates of only 33% [28]. Subsequently, the use of
repeat chest wall RT has been explored for a second curative
intent treatment despite the concerns over possible toxicity.
A multi-institutional study by Wahl et al. reviewed the
feasibility of chest wall reirradiation. Eighty-one patients
received an initial median dose of 60Gy and after local
recurrence underwent a second course of RT to the chest
wall. Median dose for the second treatment course was 48Gy.
Two-thirds of patients were free of local disease at 12months,
with the local DFS rate significantly higher in patients
without gross disease. Overall, the complete response rate
was 57% [29]. Three Grade 3 late toxicities occurred, with
patients experiencing fibrosis, infection, and lymphedema.
The lone Grade 4 event, dermatitis, occurred in a patient who
had a cumulative RT dose of ≥120Gy.
A German retrospective study from the University of
Tu¨bingen was recently published by Muller et al. reviewing
data on the role of repeat surgery and chest wall reirradiation
for curative intent. Forty-two women had received an initial
median dose of 54Gy and after local recurrences received
either surgery followed by chest wall reirradiation or chest
wall reirradiation alone. The second course of radiation
therapy was conventionally fractionated to a median dose
of 60Gy. The median interval between courses of RT was
slightly longer than that reported by Wahl et al., 53 months
versus 38 months. At a median followup of 41 months, the
estimated 5-year local control was 62% and 5-year OS was
59%. Only 2 cases of acute Grade 3 skin toxicity were noted.
Eight cases of late Grade 3 skin toxicity were reported and no
acute or late Grade 4 toxicity occurred [30].
These studies indicate that chest wall reirradiation can
provide an improved prognosis for women with local
recurrence and can be administered with acceptable acute
and late toxicities following initial treatment of breast cancer
with surgery and postoperative radiation therapy.
5. Conclusion
Despite a growing body of literature, the role of reirradiation
for locally recurrent breast cancer remains ill-defined. Repeat
breast conserving therapy has shown promise in retrospec-
tive reviews and small prospective studies. The role of PBrI
will hopefully be further elucidated by more prospective
studies, including the ongoing RTOG trial. In patients who
have previously received chest wall RT followingmastectomy,
treatment of local recurrence with reirradiation has been
shown to be feasible. Given the heterogeneity in the recurrent
breast cancer patient population, reirradiation remains an
individualized treatment decision.
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